Lung cancer

Researchers are testing whether giving adebrelimab, apatinib mesylate, and chemotherapy before surgery helps people with limited-stage small cell lung cancer. The study enrolls adults with early-stage disease that surgeons can remove. Participants receive the drug combination for…

Researchers are testing a new cell therapy called CAR001 in adults with solid tumors that have come back or stopped responding to standard treatment. CAR001 uses donor gamma-delta T cells engineered with a chimeric antigen receptor to recognize and attack cancer cells. The trial …

This early-phase trial is testing an experimental therapy called DLL3-SAVVYZ-IL18 CAR T cells in people with advanced neuroendocrine cancers, including small cell lung cancer. The treatment involves reprogramming a patient's own immune cells to recognize and attack cancer cells t…

This early-stage trial tests a personalized cancer vaccine for people with bladder or stomach cancer who still have tiny amounts of cancer DNA in their blood after surgery. The vaccine is made from unique proteins in each person's tumor and aims to train the immune system to find…

This phase 3 trial is testing whether the immunotherapy drug durvalumab, given after surgery, can prevent early-stage non-small cell lung cancer from coming back. About 306 participants who have had their tumor completely removed will be randomly assigned to receive durvalumab or…

This program offers early access to the investigational drug neladalkib for people with advanced ALK-positive lung cancer or other ALK-positive solid tumors who have run out of standard treatment options and cannot join a clinical trial. Participants must be at least 18 years old…

This early-stage trial tests an experimental drug called ACR-2316 in 100 people with advanced solid tumors that have spread or come back. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. It is for patients who have had up to 3 pr…

This Phase 3 trial tests whether adding the targeted drug calderasib to the immunotherapy pembrolizumab helps people with a specific KRAS G12C-mutated lung cancer live longer without their cancer growing. About 675 participants with advanced non-squamous non-small cell lung cance…

This Phase III trial is testing whether adding bevacizumab to the standard drug osimertinib can better control advanced EGFR-mutant non-small cell lung cancer. About 300 people with stage IIIB or IV disease will be randomly assigned to receive either the combination or osimertini…

This phase 3 trial tests whether adding the targeted pill calderasib (MK-1084) to the immunotherapy durvalumab helps people with a specific KRAS G12C-mutated lung cancer live longer without their cancer growing. About 310 participants who have finished chemotherapy and radiation …

This early-stage study tests a new oral drug, APR-1051, in about 90 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also look for early signs that the drug might…

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 470 adults will tak…

This phase II trial is testing the drug osimertinib in 46 people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). The goal is to see if the drug can shrink tumors or slow the cancer's growth. Participants will take osimertinib …

This study tests a new drug, ABBV-706, against standard treatments for small cell lung cancer that has come back or stopped responding. About 531 adults will receive either ABBV-706 or usual care (topotecan, lurbinectedin, or amrubicin) to see which works better. The goal is to s…

This study tests whether text-based support can help rural cancer survivors who smoke to quit. Participants will either receive text messages that gradually reduce cigarette use or a self-help manual. The goal is to see which approach works better for long-term smoking cessation.

This early-phase trial tests the safety of CRD3874-SI, a drug that activates the STING pathway to boost the immune system against cancer. About 81 adults with advanced solid tumors (sarcoma, Merkel cell carcinoma, and others) will receive weekly IV infusions at increasing doses. …

This Phase 3 trial is testing whether adding an experimental drug called calderasib (MK-1084) to standard immunotherapy (pembrolizumab) can keep non-small cell lung cancer from returning after surgery. The study enrolls 400 people with a specific KRAS G12C mutation whose cancer w…

This phase 2 trial is testing the immunotherapy drug pembrolizumab, given alone or with chemotherapy, in 318 Black patients with advanced non-small cell lung cancer. The goal is to see how well these treatments work in real-world settings and to find biological markers that predi…

This study tests an experimental drug called BLU-924 (SAR449336) in people with advanced pancreatic, lung, or colorectal cancers that have specific KRAS mutations. The drug is designed to block the cancer-driving KRAS protein. The trial will enroll about 265 participants to evalu…

This Phase 2 trial tests whether adding trilaciclib to the chemotherapy drug lurbinectedin can reduce severe neutropenia (a dangerous drop in white blood cells) in people with small cell lung cancer that has spread. About 30 participants will receive both drugs intravenously. The…

This study tests a drug called tarlatamab in people with advanced small cell lung cancer that has worsened after one prior treatment. About 48 participants will receive the drug by IV to see if it helps them live longer. The goal is to find a new option for patients who have limi…

This early-stage trial tests an experimental medicine called BI 3822971 in adults with advanced or metastatic solid cancers, such as lung, head and neck, breast, esophageal, bladder, vulvar, or cervical cancer, who have no standard treatment options left. The goal is to find out …

This rollover study allows up to 40 people with KRAS G12C-mutated lung or other solid tumors who are already benefiting from opnurasib in a Novartis trial to keep receiving the drug. Participants continue their current dose of opnurasib alone or with TNO155 or trametinib. The goa…

This early-phase trial is testing an oral drug called NP-101 in 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and side effects, with a secondary look at whether the drug can shrink tumors. Because it is a Pha…

This early-phase trial tests an experimental drug called HMPL-A580 in 186 adults with advanced or metastatic solid tumors that cannot be removed by surgery. The study aims to find a safe dose and check for early signs that the drug shrinks tumors. It is currently recruiting parti…

This study tests a new drug combination (alisertib plus paclitaxel) in people with small cell lung cancer who have already tried other treatments. The main goal is to find safe doses and see what side effects occur. About 50 adults will take alisertib pills and receive paclitaxel…

Researchers are testing an experimental biologic called AWT020 in adults with advanced solid tumors that have worsened after at least one standard treatment. The phase 1 trial gives AWT020 every three weeks at increasing dose levels to find the highest dose people can tolerate an…

This phase III trial is testing whether the immunotherapy drug atezolizumab, given after surgery, can prevent stage I non-small cell lung cancer from returning. About 336 patients who have had their tumor completely removed will be randomly assigned to receive either atezolizumab…

This phase 3 study compares two immunotherapy drugs—rilvegostomig and pembrolizumab (Keytruda)—each combined with standard chemotherapy, as a first treatment for people with advanced squamous non-small cell lung cancer that has a specific protein (PD-L1). About 880 participants w…

This early-stage trial tests whether a stool transplant (FMT) can help cancer patients who develop severe diarrhea or colon inflammation from immune-checkpoint inhibitor drugs. About 40 patients with various cancers will receive the transplant via colonoscopy. The main goal is to…

This phase 2 trial tests a drug called navlimetostat in about 130 people with advanced or metastatic non-small cell lung cancer that has a specific genetic change (MTAP deletion) and has worsened after other treatments. The main goal is to see if the drug can shrink tumors. Resea…

This early-stage trial tests an experimental oral drug called SHY-ONC6 in people with advanced or metastatic solid tumors (including breast, colon, lung, pancreatic, and others) that have stopped responding to standard treatments. The study aims to find a safe dose and check for …

This trial tests an experimental drug called ASP388B, given alone or alongside standard cancer therapies, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second tests that dose in…

This phase 3 trial tests whether a personalized mRNA cancer vaccine (intismeran) alone or combined with an immunotherapy drug (pembrolizumab) can prevent non-small cell lung cancer from coming back after complete surgical removal. About 876 people with high-risk stage I lung canc…

This early-phase trial is testing an experimental drug called BI-1808, alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma. The main goals are to check safety, find the best dose, and see how…

This study tests an experimental oral drug, BPI-572270, in 120 adults with advanced solid tumors (lung, colorectal, or pancreatic cancer) that have specific RAS gene mutations. The trial has two phases: first to find a safe dose and check for side effects, then to see if the drug…

This early-phase trial is testing whether combining the drug talazoparib with one of three other drugs (palbociclib, axitinib, or crizotinib) can safely help control advanced solid tumors that have spread. Talazoparib blocks cancer cells from repairing their DNA, while the other …

This phase 3 study compares ivonescimab, an experimental immunotherapy, to the standard drug pembrolizumab in 780 people with advanced non-small cell lung cancer that has high PD-L1 levels. Participants receive one of the two drugs as their first treatment. The study measures how…

This Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…

This early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…

This early-stage trial is testing a new drug called DS3610a in about 70 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can help control the cancer. P…

This study tests a new drug called AU-007 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is designed to help the immune system fight cancer. About 159 participants will receive AU-007 alone or with other medicines to find the safes…

This study tests whether adding an experimental mRNA vaccine (V940) to the immunotherapy drug pembrolizumab (Keytruda) can keep lung cancer from returning after surgery. It includes 680 people with stage II to IIIB non-small cell lung cancer whose tumors did not fully respond to …

This early-phase study is testing an experimental drug called YL217 in 220 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and look for early signs that the drug can shrink tumors. Participa…

This early-stage trial tests a new oral drug called AQUA07, alone or with another drug (lorlatinib), in about 102 people with ALK-positive non-small cell lung cancer that has spread or cannot be removed. The main goals are to check safety, find the right dose, and see how the bod…

This study tests a drug called NBTXR3 given with radiation therapy for people with locally-advanced non-small cell lung cancer who cannot have chemotherapy or surgery. The goal is to see if the combination is safe and helps control the cancer. About 40 adults with stage I to III …

This study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…

This early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…

This phase 3 trial is testing whether tarlatamab, an immunotherapy drug, can be given as a quick injection under the skin instead of a slow intravenous drip for people with relapsed extensive-stage small cell lung cancer. The study will compare the two methods to see if the injec…

This trial tests whether adding the experimental drug iadademstat to standard immunotherapy (atezolizumab or durvalumab) can help keep extensive-stage small cell lung cancer from growing. About 45 adults whose cancer responded to initial chemo-immunotherapy will receive the combi…

This Phase 3 trial will test whether a new drug called BL-M14D1 combined with atezolizumab works better than the current standard treatment for people with extensive-stage small cell lung cancer who have not had prior therapy. About 550 adults will be randomly assigned to receive…

This trial tests an experimental daily pill, VS-7375, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12D. Participants must have already tried chemotherapy and an immunotherapy drug. The study looks at whether the drug can shri…

This study tests a drug called SMS001, a new version of the chemotherapy paclitaxel, in 42 people with non-small cell lung cancer (stages Ib to IIIa). The goal is to see if a single dose after surgery can safely prevent the cancer from coming back. Researchers will monitor side e…

This phase 2 trial tests two antibody-drug conjugates (ADCs) — R-DXD and I-DXD — against standard chemotherapy in 144 people with advanced squamous non-small cell lung cancer that has worsened after initial treatment. ADCs are like guided missiles that deliver a cancer-killing dr…

This phase 3 trial tests whether adding the experimental drug MK-2870 to the standard immunotherapy pembrolizumab helps people with advanced non-small cell lung cancer live longer compared to pembrolizumab alone. The study enrolls about 614 adults whose tumors have high PD-L1 lev…

This study tests whether a daily pill called zongertinib can help prevent lung cancer from coming back in people with early-stage (Stage II-IIIB) non-small cell lung cancer that has a specific HER2 mutation. All participants have had surgery to remove their tumor and standard che…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

Researchers are running a first-in-human Phase 1 trial of HG381, an experimental drug given by intravenous injection, in adults with advanced solid tumors that have worsened after available treatments. The study aims to find out how safe and tolerable the drug is, how the body pr…

This early-stage trial is testing a new drug called IM-1617 in people with advanced solid tumors (cancers that have spread or can't be removed by surgery). The study has two parts: first, finding a safe dose, then testing that dose in more people to see how well it works and how …

This study tests a new drug called GI-108 in people with advanced or metastatic solid tumors, including lung, head and neck, pancreatic, and kidney cancers. The drug is designed to boost the immune system's ability to fight cancer. The trial will first find the safest dose, then …

This study tests whether taking special gut bacteria capsules (RMT) alongside standard chemotherapy and immunotherapy can help control advanced lung cancer. About 82 people with untreated non-small cell lung cancer will receive either RMT or a placebo. The goal is to see if the b…

This early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…

This Phase 2 trial tests whether combining lurbinectedin (Zepzelca) with durvalumab (Imfinzi) as maintenance therapy can delay cancer growth in people with extensive-stage small-cell lung cancer whose disease has not worsened after initial chemotherapy plus durvalumab. About 50 p…

This early-phase trial is testing a new radioactive drug that seeks out a protein called Nectin-4 found on many cancer cells. The drug delivers a dose of radiation directly to the tumor, aiming to destroy it while sparing healthy tissue. About 150 adults with advanced bladder, br…

This study tests a new drug called YL201 combined with atezolizumab in people with advanced small cell lung cancer. The goal is to find safe doses and see if the combination helps control the disease. About 118 adults who have not had prior treatment for this cancer will take par…

This study tests whether adding an experimental drug (EIK1001) to standard immunotherapy and chemotherapy helps people with stage 4 non-small cell lung cancer live longer or slow tumor growth. About 750 adults whose cancer has spread will receive either the new combination or a p…

This study tests a new drug, setidegrasib, against a standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific KRAS G12D mutation. The goal is to see if setidegrasib can keep the cancer from growing longer and help people live longer…

This study tests whether adding the drug MK-2870 to standard immunotherapy (pembrolizumab) after surgery can help prevent lung cancer from coming back. It is for people with stage II to IIIB non-small cell lung cancer whose tumor did not fully disappear after chemotherapy and imm…

This study tests a new drug called WJB001 combined with various chemotherapy drugs in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose, check how the body processes the drug, and see if it shrinks…

This early-phase trial is testing a new oral drug called RMC-5127, alone or combined with other drugs, in adults with advanced solid tumors that have a specific KRAS G12V mutation. The study includes people with lung, colorectal, and pancreatic cancers who have already tried stan…

Researchers are testing an experimental injection called SHR-7787 in adults with advanced solid tumors that cannot be removed by surgery or have spread. The trial aims to find a safe dose, measure how the body processes the drug, and look for early signs that it shrinks tumors. P…

This study tests whether two common heart medications—atorvastatin (a statin) and lisinopril (an ACE inhibitor)—can prevent or reduce heart damage caused by radiation therapy for chest cancers like breast, lung, and esophageal cancer. About 60 adults receiving chest radiation wil…

Researchers at Emory University are testing intensity-modulated proton therapy (IMPT) for people with small cell lung cancer. Proton therapy delivers radiation to tumors while reducing exposure to nearby healthy organs like the heart. The study enrolls 30 adults with limited or e…

This study tests an experimental gene therapy called quaratusugene ozeplasmid (Reqorsa) combined with the drug osimertinib (Tagrisso) in people with advanced EGFR-mutant non-small cell lung cancer whose cancer has stopped responding to osimertinib alone. The gene therapy delivers…

This early-stage study is testing a new drug called BGB-B2033, alone or with other drugs, in people with advanced liver, stomach, or lung cancers. The goal is to see if it is safe and how well it works. About 392 participants will take part.

This phase II trial tests whether a drug called BIO 300, made from a soy compound, can prevent severe lung inflammation (pneumonitis) in people with early-stage non-small cell lung cancer who also have interstitial lung disease. About 25 participants will receive BIO 300 along wi…

This study tests whether using a chat-based mobile app (Zalo) can help people follow through with recommended tests after an abnormal chest X-ray read by AI. About 2,692 adults in Vietnam at risk for lung cancer or TB will be randomly assigned to receive either standard results o…

Researchers are testing a new oral drug called DC05F01 in adults with recurrent ovarian cancer and other advanced solid tumors that have worsened after standard treatment. The trial aims to see how well the drug shrinks tumors, how long it keeps cancer from growing, and what side…

This early-phase study tests a new drug called BG-C9074, designed to target and kill cancer cells in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test it alone or with other cancer drugs. About 3…

This phase 2 trial tests proton beam radiation therapy in 20 adults with non-small cell lung cancer that has spread to chest lymph nodes (N2) and has been surgically removed. Proton therapy targets cancer cells while sparing healthy tissue, potentially reducing recurrence risk. R…

This study is testing an experimental oral drug called ATX-295 in people with advanced solid tumors, including ovarian cancer, that have not responded to standard treatments. The main goal is to find a safe and tolerable dose and to see if the drug can shrink tumors. About 90 par…

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

This early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…

This phase 2 trial tests whether adding two experimental drugs, imzokitug and pumitamig, to standard chemotherapy helps people with advanced non-small cell lung cancer (NSCLC) who have not had prior treatment. About 160 participants will receive either the three-drug combination …

This study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…

This early-stage trial is testing a new drug called BL-M14D1 in about 120 people with advanced small cell lung cancer or other neuroendocrine cancers that have spread or cannot be removed. The drug works by homing in on a protein called DLL3 found on these cancer cells and delive…

This study tests the immunotherapy drug atezolizumab in 200 people with advanced solid tumors (breast, lung, GI, and others). Researchers use each person's tumor DNA to see if it predicts a response. Participants get the same dose every 3 weeks. The goal is to see if DNA analysis…

This study tests a drug called adagrasib, alone or with pembrolizumab (an immunotherapy), in people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if the combination shrinks tumors and helps people live longer without t…

This early-stage trial is testing a new approach for people with advanced non-small cell lung cancer that has specific gene changes (EGFR, ALK, ROS1, or HER2). Doctors take immune cells from the patient's own tumor, boost them in the lab with a molecule called CD40L, and then giv…

This study is testing whether giving lower, less frequent doses of the cancer drug atezolizumab can still keep enough drug in the blood to fight cancer. About 30 adults with certain advanced cancers (like lung cancer or melanoma) will start with standard doses, then switch to a l…

This study tests whether combining two drugs, tepotinib and ivonescimab, is safe and works for people with advanced non-small cell lung cancer that has a specific genetic change called METex14 skipping. About 16 participants will try different doses to find the one with the fewes…

Researchers are testing a radiation schedule that delivers higher doses per session and more sessions per day for non-small cell lung cancer that grows quickly. The trial enrolls adults with confirmed high-proliferation NSCLC who are planned for chest radiotherapy, regardless of …

This phase 3 trial compares a new targeted drug, telisotuzumab vedotin, to the standard chemotherapy docetaxel in adults with a specific type of advanced non-small cell lung cancer that has a high level of a protein called c-Met. About 698 participants worldwide will receive eith…

This early-stage trial is testing a new oral drug called ISM6331 in 100 adults with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug can shrink tumors. Partic…

This study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…

This early-stage trial is testing an experimental drug called TQB6426 in people with advanced cancers that have not responded to other treatments. TQB6426 is designed to seek out a protein called GPC3 on cancer cells and deliver a chemotherapy-like payload directly to them. The s…

This study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B…

This study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…

This study tests whether adding the experimental drug obrixtamig to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer. About 670 adults with extensive-stage disease will be randomly assigned to receive either the new combination…

This study is for people who have both an autoimmune disease (like rheumatoid arthritis, lupus, or multiple sclerosis) and an advanced cancer that has spread or cannot be removed by surgery. It tests the safety and effectiveness of the immunotherapy drug nivolumab, given alone or…

This early-stage trial tests a new drug called DXP-106 in 54 people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if DXP-106 works better when given alone or with chemotherapy. Participants receive the drug by…

This phase 2 trial is testing three different doses of an investigational drug called telisotuzumab vedotin in about 150 adults with a specific type of advanced lung cancer (non-small cell lung cancer that has high levels of a protein called c-Met and no EGFR mutation). The drug …

This early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…

This early-phase trial is testing two drugs, osimertinib and tegavivint, as a first treatment for people with a specific type of advanced lung cancer (EGFR-mutant NSCLC that has spread). The goal is to find the best dose and see if the combination is safe and shrinks tumors. Abou…

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This early-phase trial tests SL-28, a cell therapy made from donor immune cells, in 60 people with advanced solid tumors (like lung, pancreatic, or breast cancer) that haven't responded to standard treatments. The study aims to find a safe dose and see if the therapy can shrink t…

Researchers are testing two experimental oral drugs, TT-10 and TT-4, in adults with advanced solid tumors such as kidney, prostate, and lung cancers that have worsened after standard treatment or cannot receive it. The drugs block adenosine receptors, which tumors use to quiet th…

This phase 2 trial tests whether adding tafolecimab (a cholesterol-lowering drug) to standard chemotherapy and the immunotherapy sintilimab helps people with extensive-stage small cell lung cancer live longer without their cancer growing. About 40 adults who have not had prior tr…

This study tests a new drug, telisotuzumab adizutecan, in people with advanced EGFR-mutated non-small cell lung cancer whose cancer has progressed after a third-generation targeted therapy. About 430 adults will receive either the new drug or standard care. The goal is to see if …

This early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …

This study tests a new combination of two drugs (trastuzumab deruxtecan and pembrolizumab) against standard chemotherapy plus pembrolizumab as a first treatment for people with advanced non-small cell lung cancer that has high levels of HER2 and low PD-L1. About 686 adults will t…

This early-stage trial is testing an experimental drug called EVOLVE104 in people with advanced bladder cancer or several types of squamous cell carcinoma (lung, esophagus, skin, and others). The study aims to find a safe dose and see if the drug can shrink tumors. It is for pati…

This study tests a new oral drug called ART6043, alone or with another drug (olaparib), in 181 people with advanced or metastatic solid tumors. The goal is to check safety, how the body processes the drug, and whether it can slow tumor growth. It is an early-stage trial, so the m…

This study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior treatment. Participants take one of two daily doses and continue as long as they benefit. Doctors regularly check tumor…

This study tests a new medicine called PF-08634404, given alone or with chemotherapy, for adults with early or locally advanced non-small cell lung cancer. The trial has three parts: before surgery, after surgery if cancer remains, or after chemoradiation. Researchers will check …

This study tests an experimental drug called BMS-986525, given alone or with the immunotherapy nivolumab (Opdivo), in 240 people whose small cell lung cancer has returned or stopped responding to standard platinum-based chemotherapy. The main goals are to check safety and tolerab…

This early-stage trial is testing a new drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The study aims to find the safest dose and see if the drug can shrink tumors. About 52…

This early-stage study is testing a new drug called calderasib (MK-1084) in people with advanced solid tumors that have a specific KRAS G12C mutation. The drug is given alone or combined with other cancer treatments. The main goals are to check safety and find the right dose. Abo…

This Phase 3 trial tests ZL-1310, a drug that delivers chemotherapy directly to cancer cells, in people with small cell lung cancer that has returned after initial treatment. About 480 participants will receive either ZL-1310 or one of three standard treatments. The study aims to…

This phase 3 trial is testing whether a combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy works better than the current standard (pembrolizumab plus chemotherapy) for people with advanced non-squamous lung cancer whose tumors have PD-L1 levels of…

This study is testing a new experimental drug called GI-101, given alone or with pembrolizumab or lenvatinib, in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults w…

This early-phase study is testing a new drug called BGB-26808, either alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 217 partici…

This study tests whether a non-invasive ventilation mask (NIPPV) can reduce the need for intubation in cancer patients with respiratory failure. Researchers will compare NIPPV plus standard oxygen therapy to standard oxygen therapy alone in 256 participants. The goal is to see if…

This study tests whether adding a new drug called navlimetostat to standard immunotherapy (pembrolizumab) and chemotherapy helps people with a specific genetic form of advanced lung cancer (MTAP deletion) live longer without their cancer worsening. About 590 participants will be …

This study tests a new drug called BMS-986507, alone or with other cancer medicines, in adults with advanced lung or breast cancer that has spread. The goal is to check safety, side effects, and how well the drugs work. About 416 participants will receive different combinations t…

This early-phase trial is testing a new oral drug called iadademstat combined with radiation therapy and the immunotherapy atezolizumab in people with extensive-stage small-cell lung cancer that has persisted, returned, or worsened after first-line treatment. The study will enrol…

This early-phase trial is testing a new drug called BG-C0902 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to two proteins (EGFR and MET) often found on cancer cells and deliver a toxic payload directly to them…

This study tests a new drug called TUB-040 for people with ovarian cancer that no longer responds to platinum chemotherapy, or with a type of lung cancer that has come back. TUB-040 is an antibody-drug conjugate, meaning it delivers a powerful chemotherapy directly to cancer cell…

This early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…

Researchers are testing an experimental radioactive drug called 177Lu-FAP-VG11 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to seek out and attach to a protein called FAP, which is found on many tumor cells. This early …

This study tests whether two experimental drugs (livmoniplimab and budigalimab) combined with chemotherapy work better than the current standard treatment (pembrolizumab plus chemo) for people with untreated metastatic non-squamous non-small cell lung cancer. About 840 adults wil…

This study tests a new treatment called DJI136, which uses a patient's own immune cells engineered to target a protein (DLL3) found on small cell lung cancer cells. The trial enrolls 80 adults with extensive-stage small cell lung cancer whose disease has progressed after standard…

This study looks at whether the immunotherapy drug durvalumab can help people with limited-stage small-cell lung cancer when given after chemoradiation. Researchers will track 200 patients in China to see how long the cancer stays under control and how safe the treatment is. The …

This study compares the standard drug osimertinib alone versus osimertinib plus chemotherapy (carboplatin and pemetrexed) in people with metastatic EGFR-mutant lung cancer who still have detectable cancer DNA in their blood after starting osimertinib. The goal is to see if the co…

This early-stage trial is testing an experimental oral drug called HW221043 in adults with advanced solid tumors who have no standard treatment options left. The study has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors or slow their gro…

This study tests a new experimental drug called PF-08634404 combined with other cancer medicines in people with advanced non-small cell lung cancer that has spread and can't be surgically removed. The trial has two parts: one combining PF-08634404 with sigvotatug vedotin, and ano…

Researchers are testing an experimental intravenous biologic called M1-c6v1 in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The Phase I trial gives escalating doses to a small group of participants to check safety, find th…

This early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…

This study tests a new drug called AZD8205, alone or with another drug (rilvegostomig), in people with advanced solid tumors like breast, ovarian, and lung cancers. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 460 adults whose c…

This phase 2 trial tests whether adding the drug narlumosbart and precise radiation therapy to standard first-line treatment can help people with advanced non-small cell lung cancer that has spread to the bones. The study will enroll 27 adults who have not had prior systemic ther…

This early-stage trial is testing an experimental drug called MK-4716, alone or combined with other cancer drugs, in people with advanced solid tumors that have a KRAS mutation. The main goal is to see if the drug is safe and tolerable. About 250 participants will be enrolled.

This study tests a new drug called telisotuzumab adizutecan (ABBV-400) combined with an immunotherapy drug (budigalimab or pembrolizumab) in people with advanced non-squamous lung cancer who have not had prior treatment. The goal is to find the best dose that is safe and effectiv…

This early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…

Researchers are testing whether adding tislelizumab and anlotinib after chemoradiotherapy can help people with limited-stage small cell lung cancer live longer without their cancer coming back. The study enrolls adults aged 18 to 75 whose cancer has not worsened after concurrent …

This study tests a new drug called ABBV-706 combined with the immunotherapy atezolizumab as a first treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. About 180 adults will receive either the new combination at one of two dose…

This phase 3 trial is testing a new combination of drugs (BMS-986489) plus chemotherapy against a standard treatment (atezolizumab plus chemotherapy) for people with extensive-stage small cell lung cancer, a fast-growing cancer. The study aims to see if the new combo helps people…

This early-phase study tests a new targeted therapy called MK-8294 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety, see if people can tolerate it, and find the highest safe dose. About 67 participants will receive the drug, and…

This study tests a drug called sotorasib in people with advanced non-small cell lung cancer that has a specific change in the KRAS gene (called G12C). Participants have not yet received any treatment for their advanced cancer. The goal is to see if sotorasib is safe and effective…

This trial tests a new drug called TUB-030 in adults with advanced solid tumors, including head and neck, lung, and breast cancers. The goal is to find the safest and most effective dose. Participants receive the drug every three weeks and are monitored for side effects and tumor…

This study tests a new gene therapy (quaratusugene ozeplasmid) plus an immunotherapy drug (atezolizumab) as maintenance treatment for people with extensive stage small cell lung cancer. The goal is to see if the combination can keep the cancer from growing longer than standard ca…

This study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…

This phase 2 trial is testing two experimental drugs, ubamatamab and REGN7075, alone or together, in 300 people with advanced or metastatic non-small cell lung cancer who have already had standard treatments. A third drug, sarilumab, may be used to manage immune-related side effe…

Researchers are testing whether combining SX-682, an experimental drug that blocks CXCR1 and CXCR2, with proton craniospinal irradiation is safe and effective for people with leptomeningeal disease from melanoma or non-small cell lung cancer. Participants take SX-682 by mouth twi…

This study tests whether a new drug combo (sotorasib plus chemotherapy) works better than the current standard (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer that has a specific KRAS G12C gene change and low PD-L1 levels. About 750 adults wh…

This study is testing a new experimental drug called BG-75098, given alone or with other medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…

This early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …

This study tests a new drug, BAY 3713372, for people with solid tumors that have a specific genetic deletion called MTAP. The drug is designed to kill cancer cells while sparing normal cells. The trial will first find a safe dose, then test how well it works in up to 450 particip…

This phase 2 trial tests a combination of tarlatamab (a targeted immune therapy), chemotherapy, and atezolizumab in 50 adults whose lung cancer has transformed from a common type (adenocarcinoma) to a more aggressive small cell form after initial treatment. The goal is to see if …

Researchers are running a Phase I trial of VRT106, an experimental biological therapy given by intravenous drip, in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The trial enrolls about 12 people aged 18 to 75. It aims to f…

This Phase 1 trial tests a new drug called BL-M07D1 in 280 adults with advanced HER2-positive cancers, including breast, lung, and stomach cancers. The study aims to find safe doses and check for early signs of tumor shrinkage. Participants must have tried at least two prior trea…

This study tests different drug combinations in people with early-stage non-small cell lung cancer that can be removed with surgery. The drugs are chosen based on specific genetic markers in each person's tumor. The goal is to see if these treatments shrink the tumor before surge…

This early-stage trial tests the safety of a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have no standard treatment options. About 101 participants will take part. The study has two parts: first testing KK2269 al…

This early-phase study tests a new drug called FORX-428 in about 40 adults with advanced solid tumors that have certain gene changes (like BRCA1/2 mutations). The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their growth. …

This early-phase study tests a new drug called EPI-326 in about 110 people with advanced lung or head & neck cancers that have specific EGFR mutations. The drug is a bispecific antibody designed to target cancer cells more precisely. The main goals are to check safety, find the r…

This study is testing a new drug called MK-3120 in people with advanced solid tumors that have spread and cannot be removed by surgery. The main goal is to see if the drug is safe and tolerable. About 270 participants will receive the drug by IV infusion. The study also looks at …

This study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.

This early-stage study tests a new drug called TQB2922, given as a shot under the skin, in 42 people with advanced non-small cell lung cancer that has not responded to standard treatments. The drug is a bispecific antibody designed to block two cancer-related proteins (EGFR and c…

This study tests an experimental drug called SHR-4610 in 258 adults with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The trial has two phases: first, finding the safest dose, and second, checking how well the drug shrinks…

This phase 3 trial compares three ways of giving the immunotherapy drug toripalimab to people with stage II-IIIA non-small cell lung cancer that can be removed with surgery. Participants will receive toripalimab either before surgery (neoadjuvant), after surgery (adjuvant), or bo…

This phase 2 trial tests whether combining two targeted drugs—lazertinib and tepotinib—can shrink tumors in people with advanced EGFR-mutant non-small cell lung cancer whose disease has worsened after initial lazertinib treatment due to MET gene changes. About 47 participants wil…

This Phase 3 trial is testing a new oral drug, sevabertinib, against standard intravenous chemotherapy for people with advanced non-small cell lung cancer that has specific HER2 mutations. About 444 participants will be randomly assigned to receive either sevabertinib twice daily…

This study tests whether adding a new drug (BL-B01D1) to the standard pill osimertinib can help people with a certain type of Stage III lung cancer stay cancer-free longer. Participants must have an EGFR gene mutation and have already completed chemotherapy and radiation without …

Researchers are testing whether combining pembrolizumab, an immunotherapy given intravenously every three weeks, with lenvatinib, a daily oral drug, can help adults with metastatic non-small cell lung cancer that carries a RET gene rearrangement and has worsened after prior treat…

This early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced solid tumors that have spread. About 115 adults whose cancer has worsened after at least one prior treatment will receive the combination. The main goal is to chec…

This trial is testing an experimental drug called SA53-OS in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by blocking a protein called MDM2, which may help slow or stop tumor growth. The study has two parts: first,…

This trial studies people with early-stage non-small cell lung cancer who are having surgery to remove the tumor. During surgery, doctors usually also remove lymph nodes from a specific area called station 4L. The trial randomly assigns half of the participants to have those lymp…

This study tests a new drug called TAK-505 in adults with advanced solid tumors that cannot be removed by surgery. The main goals are to check safety, find the best dose, and see if the drug can shrink or slow cancer growth. About 151 people with certain cancers, such as stomach,…

This study tests a drug called repotrectinib in 20 people with a specific type of lung cancer (ROS1-positive NSCLC) that has spread to the brain. The main goal is to see if the drug can shrink or eliminate brain tumors. Participants will take the drug by mouth, and doctors will m…

This early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…

This early-stage study tests a new drug called BBO-10203 in people with advanced solid tumors (breast, lung, or colorectal cancer) that have not responded to standard treatments. The drug is designed to block two cancer-driving proteins (PI3K and RAS). Researchers will check safe…

Researchers are running a phase I/IIa trial of SGT003, an experimental intravenous drug, in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: a dose-escalation phase to find a safe dose and a dose-expansion phase to look fo…

This phase 1 trial is testing a new drug called ADCE-T02 in people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target a protein called tissue factor found on many cancer cells. The main goals are to…

This phase 2 trial is testing a drug called tarlatamab in 40 people with advanced small-cell lung cancer or other poorly differentiated neuroendocrine cancers. The drug is given by IV and aims to shrink tumors. Researchers will also study blood and tumor samples to understand why…

This early-phase study tests a new cell therapy called NK510 in 12 people with advanced non-small cell lung cancer that no longer responds to PD-1 inhibitors. The treatment uses specially designed natural killer cells that are blocked from a protein called TIGIT, aiming to boost …

This early-stage trial tests AGX101, a drug that delivers chemotherapy directly to cancer cells by targeting a protein called TM4SF1. About 80 adults with advanced solid tumors (like breast, prostate, or pancreatic cancer) who have run out of standard options will receive the dru…

This study tests whether the drug divarasib can prevent lung cancer from coming back in people with a specific gene mutation (KRAS G12C) who have already had surgery and chemotherapy. About 400 adults with stage II-III non-small cell lung cancer will be randomly assigned to recei…

This early-phase study tests a new radioactive drug, 225Ac-ETN029, in 116 adults with advanced DLL3-positive cancers like small cell lung cancer or neuroendocrine tumors. The main goal is to check safety and find the right dose, while also seeing if the drug can shrink tumors. Pa…

This trial investigates a new drug called GEN1119 for people with certain solid tumors that have not improved with standard treatments or for whom no standard treatment exists. The study is divided into parts: first, to find safe and effective doses, then to test those doses in m…

This early-stage trial tests a new drug called IAM1363 in adults with advanced cancers that have HER2 alterations, including breast, lung, and stomach cancers that have spread to the brain. The study aims to find the safest dose and see if the drug can shrink tumors. About 383 pa…

This early-phase trial is testing a new experimental drug, BNT317, in 39 people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the right dose, and see how the body handles it. It is too soon to know if …

This study tests two experimental drugs, MK-6070 and ifinatamab deruxtecan (I-DXd), alone or together, in people with advanced small cell lung cancer that stopped responding to standard treatment. The goal is to see if these combinations can shrink tumors and are safe. About 262 …

This phase III trial is investigating whether surgically removing the primary lung tumor, in addition to continuing the targeted therapy osimertinib, can prolong the time before disease progression in patients with EGFR-mutant non-small cell lung cancer that has spread to a limit…

This early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …

This study tests whether adding AGuIX gadolinium-based nanoparticles to standard brain radiation can better control brain metastases that are at high risk of coming back. About 134 adults with certain cancers (like melanoma, lung, breast, or colorectal) that have spread to the br…

This early-stage study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The main goals are to find the safest dose and check for side effects. About 193 participants will take the drug alo…

This early-phase trial tests a new drug called FID-022 in 24 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. The drug contains two active components, including irinotecan, which is …

This study looks at whether taking the targeted drug icotinib after surgery helps people with early-stage non-small cell lung cancer that has EGFR mutations live longer. Researchers will compare patients who received icotinib after complete tumor removal with those who only had r…

This study tests a drug called divarasib, either alone or with other cancer treatments, in people with advanced lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if the drug is safe and works to shrink or control the cancer. About 320 people who have …

This Phase II trial tests an experimental drug called SHR-1826 in about 300 people with advanced non-small cell lung cancer (NSCLC). The drug is given alone or combined with other cancer treatments to see if it can shrink tumors and improve outcomes. Researchers will also monitor…

This trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …

This study tests whether a new drug (divarasib) combined with immunotherapy (pembrolizumab) works better than standard chemotherapy plus immunotherapy for people with a specific genetic mutation (KRAS G12C) in advanced non-small cell lung cancer. About 600 adults who have not had…

This clinical trial is testing a new drug called TQB6411 in people with advanced lung cancer. The study has two phases: first to find the best dose, then to see how well it works. About 465 participants will receive the drug every 21 days. Researchers will measure tumor shrinkage…

This early-stage study tests a new drug called NPX372 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the body's immune cells recognize and attack cancer cells. The main goals are to check the drug's safety and fin…

This phase 3 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy after surgery can help prevent non-small cell lung cancer from coming back. About 1,210 people with stage II to IIIB lung cancer will receive either chemo plus pembrolizumab toge…

This phase 3 study is testing whether adding an experimental pill called calderasib (MK-1084) to the immunotherapy drug pembrolizumab (Keytruda) works better than pembrolizumab alone for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and high PD-L1 …

This Phase 3 study tests whether adding olomorasib (a targeted pill) to standard immunotherapy (pembrolizumab or durvalumab) works better than immunotherapy alone for people with KRAS G12C-mutant non-small cell lung cancer. The trial has two parts: one for patients whose cancer w…

This global study is testing whether adding the experimental drug olomorasib to standard immunotherapy and chemotherapy can help people with a specific genetic subtype of advanced non-small cell lung cancer (KRAS G12C mutation). About 1,264 participants will receive either the ne…

This study tests a new drug, LY4050784, in people with advanced solid tumors that have a specific change in the SMARCA4 gene. The goal is to see if the drug is safe and works, either alone or with other cancer treatments. About 340 adults whose cancer has not responded to standar…

This phase 3 trial compares a new drug called pumitamig to the standard drug pembrolizumab as a first treatment for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1 (at least 50%). The study will enroll 750 participants and measure ho…

This study follows 800 Chinese patients with early-stage ALK-positive non-small-cell lung cancer who took alectinib after surgery to see how long they stay cancer-free. Researchers will collect real-world data on disease-free survival and patient characteristics. The goal is to u…

This study tests an experimental oral drug called GS-1206 in adults with advanced or metastatic solid tumors that have a specific genetic mutation. The main goals are to evaluate the drug's safety, tolerability, and how the body processes it. Participants must have tumors that ha…

This phase 3 study compares the experimental drug pumitamig to the standard treatment durvalumab in people with stage III lung cancer that cannot be removed by surgery. Participants must have finished chemoradiation without their cancer getting worse. The main goal is to see if p…

This early-phase trial tests a new radioactive drug, 177Lu-INN805, in 10 people with advanced solid tumors (like head & neck, lung, breast, or sarcoma) that haven't responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers wi…

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

This early-phase trial is testing a combination of two drugs—FC084CSA and tislelizumab—in people with advanced solid tumors that have stopped responding to standard treatments. The study aims to find the safest dose and see if the combo can control tumor growth. Only 33 participa…

This study compares an experimental drug (PF-08046054) to standard chemotherapy (docetaxel) in about 680 adults with advanced PD-L1 positive non-small cell lung cancer that has worsened after prior treatments. Participants are randomly assigned to receive one of the two drugs by …

This early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…

This trial tests an experimental drug called DS-2243a in adults with advanced solid tumors, including sarcoma, that have spread or cannot be removed surgically. The study has two parts: first, researchers find the safest dose by giving increasing amounts to small groups; then, th…

This early-stage study tests a new medicine called PF-08046033 in adults with advanced lung, esophageal, or skin cancers that have spread or can't be removed. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug may he…

This study tests a new drug called AVZO-1418 in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if it shrinks tumors. About 480 adults will take part, receiving the drug alone or with other treatments.

This phase 3 trial compares a new targeted drug, datopotamab deruxtecan (Dato-DXd), against the standard chemotherapy docetaxel in 400 people with advanced or metastatic non-squamous non-small cell lung cancer that lacks certain gene mutations. The goal is to see if Dato-DXd can …

This study tests a combination of two targeted drugs—sotorasib and trastuzumab deruxtecan—in people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The goal is to find the safest dose and see how well the combo works at shrinking tumors. About 37 …

This trial tests an experimental drug called CFT8919 in people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to find the safest dose and see whether the drug can shrink tumors. Participants take CFT8919 capsules twice daily and undergo regular ch…

This early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…

This trial tests an experimental drug called ODM-216 in adults with advanced solid tumors, which are cancers that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second checks how well that dose fights the cancer. Researc…

This trial tests whether tarlatamab, a drug that helps the immune system attack cancer cells, can improve survival in people with advanced small-cell lung cancer whose general health is poor. The study includes 57 participants who have already had at least one prior treatment. Re…

This study tests a new drug, LY4170156, designed to attack cancer cells with a specific marker (folate receptor alpha). It is for people with advanced solid tumors like ovarian, lung, or breast cancer that have not responded to other treatments. The trial has two parts: first fin…

This phase III trial compares adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in adults aged 70+ with advanced non-small cell lung cancer. The goal is to see if the combination improves survival. About 304 participants will be enrolled.

This early-phase study tests an experimental drug called PF-08046876 in about 310 adults with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas that have not responded to standard treatments. The drug is a type of 'antibody drug conjugate' designed to s…

This study tests a new drug, BNT327, combined with chemotherapy and other agents in people with advanced non-small cell lung cancer who have not had prior treatment. The trial will enroll about 1,260 participants across multiple sites worldwide. The goal is to see if the combinat…

This early-phase trial tests an experimental drug called D3S-002, taken as a daily pill, in adults with advanced solid tumors that have MAPK pathway mutations. The study has two parts: first, finding a safe dose, and second, testing that dose alone or with another drug (D3S-001) …

This trial tests an experimental drug called FH-006 in 150 people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if FH-006 is safe, tolerable, and can shrink tumors. Researchers will measure how the drug moves through the body and …

This early-stage study tests a new treatment called ZI-MA4-1, made from specially engineered immune cells, in people with advanced ovarian, lung, sarcoma, or head and neck cancers that have not responded to other therapies. The treatment aims to help the body's immune system atta…

This early-phase study tests a daily oral drug called CGT4255 in 100 adults with advanced solid tumors that have ERBB2 genetic changes or HER2 overexpression. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors, including in the brain. The …

This study tests a new daily pill called TRI-611 for adults with advanced ALK-positive non-small cell lung cancer (NSCLC) that has not responded to other treatments. The trial has two parts: first, finding the safest dose, and second, seeing how well it shrinks tumors in differen…

This extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …

This early-phase trial is testing an experimental drug called CT7439, taken as a capsule, in about 50 people with solid tumors that have spread or cannot be removed. The study will first test CT7439 alone, then in combination with other cancer treatments. The main goals are to ch…

This study tests an experimental drug called SKB565 in 180 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The trial has three stages to find the safest dose, check how the drug moves through the body, and see if it shrinks tum…

This study tests whether a team of specialists—including surgeons, oncologists, and geriatricians—can create better treatment plans for elderly lung cancer patients. 2,000 people aged 60-90 will receive personalized care based on their overall health and cancer type. The goal is …

This early-stage study tests a new drug called MK-4884 in about 120 people with advanced or metastatic solid tumors (colorectal, kidney, lung, or bile duct cancer). The main goal is to check the drug's safety and find the right dose. Researchers will monitor side effects and how …

This early-stage trial tests a new drug called VBC101 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to attach to two cancer-related targets (EGFR and cMET) and deliver a toxic payload directly to cancer cells. The s…

This phase II trial tests whether adding local treatments like surgery or radiation to the immunotherapy drug durvalumab can help control stage III non-small cell lung cancer that has progressed after chemoradiation and durvalumab. About 51 participants with 3 or more growing tum…

This Phase 2 trial tests an oral drug called BAY 2927088 (sevabertinib) in about 111 adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. Participants take a 20 mg tablet daily in 3-week cycles u…

This early-stage trial tests an experimental drug called BBO-8520 in 350 people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The drug is taken as a pill and aims to block cancer growth. The study will check for safety, side effects, and…

This study tests an experimental drug called IDP-001 in people with advanced or metastatic solid tumors, including certain lung, head and neck, and other cancers. The trial has two phases: first to check safety and find the right dose, then to see if the drug can shrink tumors. A…

This Phase 3 trial tests whether adding a maintenance drug (sacituzumab tirumotecan) after initial chemo-immunotherapy improves survival in people with metastatic squamous non-small cell lung cancer. About 851 participants will receive pembrolizumab plus chemotherapy, then either…

This phase 2 trial tests an oral drug called lirafugratinib in 30 adults with advanced solid tumors (excluding bile duct cancer) that have an FGFR2 gene fusion or rearrangement. Participants take the drug regularly and visit the clinic for checkups. The main goal is to see if the…

This study tests a new drug called IPN01203 in about 102 adults with advanced solid tumors that have spread and stopped responding to immunotherapy. The trial has two parts: first, finding a safe dose, then testing low versus high doses to see if the drug can shrink tumors. Parti…

This phase 2 trial tests a combination of three drugs (tislelizumab, anlotinib, and nab-paclitaxel) given before surgery to people with stage III non-small cell lung cancer. The goal is to see if this approach can eliminate or greatly reduce the tumor before it is removed. The st…

This study tests whether adding a precise type of radiation therapy (I²-PORT) after lung cancer surgery can help prevent the cancer from coming back. Participants have non-small cell lung cancer with remaining cancer in lymph nodes after initial treatment. The trial compares stan…

This early-phase trial is testing a new drug called KIN-2787 (exarafenib), alone or combined with another drug (binimetinib), in 400 adults with advanced solid tumors that have BRAF or NRAS mutations. The main goals are to check safety, find the best dose, and see if the drug can…

This study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…

This early-stage trial tests an experimental drug called MRTX1719 in adults with advanced solid tumors that have a missing MTAP gene. The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants with cancers like mesothelio…

This program provides early access to an experimental drug called ifinatamab deruxtecan (I-DXd) for people with extensive-stage small cell lung cancer who have already tried at least two prior treatments, including platinum-based chemotherapy. It is for patients who have no other…

This study tests a new targeted therapy called MK-1084, alone or combined with other drugs, in 190 people with advanced non-squamous non-small cell lung cancer that has a specific KRAS G12C mutation and has worsened after prior treatments. The main goals are to check safety and s…

This trial tests whether adding electroacupuncture at a specific point below the knee, called Zusanli (ST36), to standard chemotherapy and immunotherapy can help shrink tumors in people with non-small cell lung cancer before surgery. The study includes 82 adults with this cancer …

This phase 2 trial tests a new drug called SKB571 combined with other cancer medicines in 150 people with non-small cell lung cancer. The goal is to see if the combination can shrink tumors and control the disease. Participants will receive the drugs by injection or mouth, and re…

This study gives people with cancer continued access to an experimental Roche treatment they were already receiving in a previous trial. It is for patients who still need the drug and cannot get it locally. The goal is to keep providing the treatment and monitor any side effects.

This early-phase study tests a new drug, ASP2998, that targets a protein called TROP2 found on many solid tumors. The drug is given alone or with standard treatments like pembrolizumab or carboplatin. The main goals are to check safety and find the right dose. About 428 adults wi…

This phase I/II platform trial tests several drug combinations, including evorpacept, trastuzumab deruxtecan, zanidatamab, tucatinib, and TTX-MC138, in people with advanced solid tumors, especially metastatic breast cancer. The goal is to find safe and promising regimens that cou…

This phase 2 trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy and a tailored radiation plan can help people with stage III non-small cell lung cancer. The study will enroll 35 adults who cannot have surgery. Researchers will track how long the…

This early-stage study tests a new drug (tolododekin alfa) combined with an existing immunotherapy for people with advanced non-small cell lung cancer. The goal is to see if the combination can shrink tumors or slow disease progression. About 60 participants will join, including …

This early-phase study tests a new drug called DS5361b, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This study tests an experimental oral drug called STX-721 in people with advanced non-small cell lung cancer that has specific EGFR or HER2 gene mutations. The trial has three parts: first finding a safe dose, then confirming the best dose, and finally expanding to more participa…

This early-phase trial tests a new drug called NEOK001 in people with advanced solid tumors that have stopped responding to standard treatments. NEOK001 is designed to deliver a cancer-killing agent directly to tumor cells by targeting two specific proteins. The study will first …

This early-phase study tests an experimental therapy called FT836, a ready-made CAR T-cell treatment, in people with advanced solid tumors like lung, colorectal, breast, ovarian, endometrial, or head and neck cancers that have not responded to prior treatments. The main goals are…

This Phase 2 trial tests whether combining two oral drugs, luvometinib and anlotinib, can shrink tumors in people with KRAS-mutated non-small cell lung cancer that has spread and stopped responding to prior treatment. About 48 adults will receive different dose combinations. The …

This study tests a new oral drug, STX-241, in people with advanced non-small cell lung cancer that has become resistant to standard targeted therapies. The drug is designed to reach the brain and attack cancer cells with specific genetic changes. The trial aims to find the safest…

This study is testing two new blood tests designed to help doctors detect cancer in people who have symptoms that might be cancer. The study will involve 1,650 adults aged 45 and older who are already undergoing medical tests for possible cancer. The goal is to see how well these…

This study tests an experimental imaging agent (89Zr-DFO-REGN5054) that may help visualize immune cells called CD8+ T cells in tumors. About 50 people with advanced solid cancers will receive the imaging agent along with the immunotherapy drug cemiplimab. The main goal is to chec…

This study explores whether a biosensor using trained laboratory animals can detect non-small cell lung cancer (NSCLC) by smelling unique chemicals in urine. Participants include people with and without NSCLC, as well as those suspected of having it. The goal is to see if this an…

This trial is testing whether advanced PET-CT scans can spot early signs of heart damage caused by standard radiation therapy for locally advanced non-small cell lung cancer. Ten adults with stage III lung cancer will receive a special PET-CT scan before and three months after th…

Researchers are developing an artificial intelligence model that reads preoperative CT scans and clinical data to predict whether lung cancer associated with cystic airspaces has high-risk features. The study includes 600 patients with non-small cell lung cancer who had surgery a…

The ORACLE study watches people who have finished treatment for early-stage solid tumors, such as lung, breast, colon, and pancreatic cancers. Researchers want to see if a blood test called Guardant Reveal can find tiny traces of tumor DNA that might signal the cancer is coming b…

Researchers are studying whether a blood test called Guardant360 can measure how well cancer treatment is working in people with advanced lung, colorectal, or breast cancer. The test looks for tumor DNA that cancer cells release into the bloodstream. Participants give blood sampl…

This study is testing a new blood test to find early-stage lung cancer in heavy smokers who have no symptoms. Researchers will collect blood samples from 350 current or former smokers aged 30-80, including those with and without lung cancer. The goal is to see if the test can det…

Researchers are developing a blood test that uses DNA methylation patterns and machine learning to detect multiple types of cancer at an early stage. The PROFOUND study collects blood samples from people newly diagnosed with cancer and from people without a confirmed cancer diagn…

Researchers at Erasmus Medical Center are testing whether a fluorescent imaging agent can highlight cancer cells on the surface of tumor tissue removed during surgery. The study involves 200 adults with solid tumors who are scheduled for surgery. After the tumor is removed, the d…

Researchers at Indiana University are testing an educational program called ED-LCS that teaches emergency department patients about lung cancer screening. The study enrolls adults aged 50 to 80 who have smoked at least 20 pack years and quit within the past 15 years, making them …

This trial tests an experimental imaging agent called [68Ga]Ga-DWJ155 in adults with advanced cancers of the breast, lung, or stomach. The agent is designed to attach to tumor cells and show up on PET scans, helping doctors see where cancer has spread. Researchers will measure ho…

This study tests whether a radioactive tracer called 18F-S16/T807 can help diagnose tau-related brain diseases. Tau is a protein that builds up abnormally in conditions like Alzheimer's and other neurodegenerative disorders. Researchers will give 500 adults a single injection of …

This study is testing a special type of PET/CT scan that looks for a protein called PD-L1 on cancer cells. The goal is to see if this scan can find tumors and their spread more accurately than standard imaging. About 500 adults with suspected or known PD-L1-related cancers will r…

This study tests whether PET/CT scans using two radioactive tracers, 18F-92/AV45 and 11C-PIB, can detect beta amyloid buildup in the brain. Researchers will enroll 500 adults with suspected or known neurodegenerative diseases linked to amyloid. Each participant receives one injec…

This trial tests whether an injected tracer called HED, seen on PET/CT or MRI scans, can help diagnose diseases of the sympathetic nervous system, the part of the body that controls automatic responses like heart rate and blood pressure. Researchers will scan 500 adults who have …

This trial investigates whether a femtosecond laser combined with an artificial intelligence model can diagnose lung cancer from fresh tissue samples as accurately as the standard frozen section method. About 294 adults scheduled for lung surgery will have their tumor specimens e…

This study looks at whether people with unexplained weight loss who are at high risk for lung cancer are more likely to develop the disease. Researchers will use low-dose CT scans and blood tests to screen 409 participants over one year. The goal is to see if adding weight loss t…

This study aims to see if a new blood test can accurately detect lung cancer by analyzing RNA from platelets. Researchers will collect blood samples from 240 adults with lung cancer or suspicious lung nodules. The goal is to validate whether this AI-powered test can distinguish b…

This trial compares two established biopsy methods for small lung nodules (≤2 cm): CT-guided percutaneous biopsy and shape-sensing robotic-assisted bronchoscopy with cone-beam CT. The goal is to see which approach is more effective at diagnosing cancer and which has fewer complic…

This study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…

Cancer patients with a central catheter can develop a blood clot in the upper arm. After at least three months of standard blood-thinning treatment, this trial tests whether switching to a lower, preventive dose of apixaban can stop new clots from forming. Participants stay on th…

This study tests whether giving people a personalized report about their cancer risk and screening options helps them complete recommended cancer tests. Adults aged 45 to 74 who are at high risk for lung, breast, colorectal, upper gastrointestinal, or liver cancer are invited to …

This study tests whether taking a daily statin (rosuvastatin) for one year can safely prevent life-threatening blood clots in people with cancer. Current clot-preventing drugs raise bleeding risks, so a safer option is needed. The trial will enroll 4,000 adults with newly diagnos…

This phase 3 trial tests an experimental drug called REGN7508 to prevent blood clots in people with solid tumors who are receiving cancer treatment. About 1,120 participants will receive either the drug or a placebo. The study measures how well the drug prevents clots and checks …

Researchers are testing whether giving targeted radiation to lung tumors before a lung transplant can create an immune response that helps the body fight cancer. The trial enrolls adults with end-stage lung disease and hard-to-treat lung cancer who need a transplant. The goal is …

This trial tests whether drinking 40 mL of extra-virgin olive oil four hours before lung cancer surgery can reduce the risk of chylothorax, a rare but serious complication where lymphatic fluid leaks into the chest. About 1,036 adults with resectable lung cancer will be randomly …

This study tests a program called ICCAN that gives cancer patients extra help with social and economic needs, like finding resources and monthly check-ins. Researchers want to see if this support helps patients complete their cancer treatment and improves their quality of life, c…

This study tests a program to help long-term lung cancer survivors feel more socially connected and improve their quality of life. Thirty survivors will be randomly assigned to either the program or a comparison group. The program uses techniques from cognitive behavioral therapy…

Researchers at the University of Hong Kong are evaluating a survivorship program that sorts cancer patients into moderate or high needs after treatment. People with moderate needs receive weekly or bi-weekly e-intervention videos on managing distress and weight, with peer volunte…

This pilot study tests two surgical methods—targeted muscle reinnervation (TMR) and regenerative peripheral nerve interfaces (RPNI)—alone and together to reduce chronic and phantom limb pain in cancer patients who have had an amputation. About 45 adults will be randomly assigned …

Researchers are testing whether an AI-generated, personalized discharge plan improves the quality of discharge teaching and recovery for people who had lung cancer surgery. The trial enrolls 156 adults who had surgery for stage I to III lung cancer and are going home to recover. …

This study tests whether a nerve block given through a small port under the skin can help control chest pain in people with advanced lung cancer. The block delivers numbing medicine near the chest wall nerves. Researchers will compare pain levels and side effects in 180 patients …

This study tests whether different types of massage can lower anxiety in cancer patients while they receive chemotherapy. Fifty adults who already have high anxiety and are at least one cycle into chemo will receive massage during their infusion sessions. Researchers will measure…

This study is testing whether a virtual, 8-session group therapy program can help cancer patients find meaning and reduce emotional distress. Researchers at MD Anderson Cancer Center will enroll 72 adults with a history of cancer. Participants will attend weekly 90-minute session…

This phase 3 trial compares lattice radiation therapy (LRT) to standard radiation for reducing pain from large solid tumors (at least 5 cm). About 148 adults whose tumors cannot be surgically removed will be randomly assigned to one of the two radiation approaches. The main goal …

This study tests whether a single injection of RE104 can reduce symptoms of depression or mixed depression and anxiety in people with adjustment disorder caused by a serious medical illness like cancer, ALS, multiple sclerosis, Parkinson's disease, or idiopathic pulmonary fibrosi…

Chemotherapy often causes nausea and vomiting, which is especially hard for children. This study tests a new IV drug called NEPA (fosnetupitant/palonosetron) to prevent these side effects in kids with cancer. The trial has two parts: first, an open-label phase to find the right d…

This study tests whether an artificial intelligence (AI) app can improve quality of life, anxiety, and depression in people with cancer who are already receiving psychotherapy. About 60 participants will be randomly assigned to either get the AI app alongside their usual therapy …

Researchers compare two robotic surgery approaches for removing lung tumors in adults with non-small cell lung cancer. Participants are assigned at random to either biportal surgery, which uses two incisions, or multiportal surgery, which uses several small ports. The study track…

Researchers are studying whether nutritional support helps people with advanced lung cancer maintain their weight, strength, and quality of life during chemotherapy. The trial enrolls 100 adults with high nutritional risk. Participants receive dietary advice or a structured nutri…

This study tests if the drug ustekinumab can control diarrhea and colon inflammation caused by immune checkpoint inhibitors in cancer patients. Ten adults with solid tumors who have moderate to severe symptoms will receive ustekinumab and be monitored for side effects and symptom…

This study tests a flexible palliative care program for people with advanced heart failure or certain cancers. The program adds more team members—like a social worker or nurse—as symptoms get worse. The goal is to improve quality of life and match care to each person's changing n…

This pilot study tests a 4-week personalized exercise program for people aged 70 and older who are about to have cancer surgery. Participants follow daily exercises at home using a smartphone app. The goal is to see if this approach improves their physical fitness before the oper…

This study compares standard palliative radiation for lung tumors with a newer, more focused technique that delivers a higher dose while sparing the esophagus. The goal is to improve or maintain quality of life by better controlling symptoms and reducing side effects. About 141 a…

Cancer treatment often leaves patients with a deep, lasting tiredness that few treatments can fix. Researchers are testing whether guarana, a caffeine-rich Amazonian plant, can reduce that fatigue and improve daily life. The study gives 60 people with breast, lung, colorectal, ce…

This study tests a special mental health program called DESCANSO/REST for Spanish-speaking Latino cancer patients who feel depressed, tired, or have trouble sleeping. The program is delivered through telehealth (video or phone calls). Researchers want to see if it is practical an…

This pilot study is testing a combined program of mobile health exercise and cognitive rehabilitation for older cancer survivors (age 60+) who have concerns about memory or thinking after treatment. The program uses a smartphone app for exercise tracking and group workshops for b…

This study observes about 700 people with lung or liver cancer who are already receiving atezolizumab as a shot under the skin. Researchers want to see how satisfied patients are with this treatment and how it affects their quality of life. The study does not test a new drug but …

This study tests whether using a virtual reality helmet during painful medical procedures (like needle sticks or bone marrow tests) can reduce pain in children with cancer. About 74 children aged 6 to 18 will be split into two groups: one gets standard care plus the VR helmet, th…

This phase 2 trial at MD Anderson Cancer Center is testing whether psilocybin-assisted psychotherapy can safely help ease depression and anxiety in 30 adults with advanced cancer who are on maintenance therapy. Participants receive either psilocybin or a placebo (niacin) along wi…

This trial tests an educational program called A-PACT for people with solid tumors who are at high risk of decline. Trained lay health workers coach patients on how to discuss their care goals and end-of-life wishes with their medical team. The study will see if this reduces unpl…

This study tests a 4-month coaching program called SONATA that helps older adults (age 60+) with advanced cancer build a support network of family and friends. The goal is to see if this social support makes it easier to stick with treatment and feel better. About 330 patients an…

This study tests whether a walking program and cognitive rehabilitation exercises can improve memory and thinking in people aged 65 and older who have finished cancer treatment. Forty participants will be randomly assigned to one of four groups: exercise only, cognitive training …

This study tests whether regular phone check-ins and counseling can help people on oral cancer drugs feel better and avoid hospital visits. 600 patients will be assigned to symptom monitoring alone, or monitoring plus a self-help handbook and phone counseling for anxiety or sadne…

This study tests whether a wearable device and digital platform can help people recover better after lung cancer surgery. About 126 patients with non-small cell lung cancer will either use the wearable system or receive standard care. The system tracks heart rate, oxygen levels, …

Researchers are testing whether a home-based prehabilitation program can help older adults with non-small cell lung cancer prepare for surgery. The program combines aerobic exercise, breathing muscle training, functional and chest expansion exercises, nutrition guidance, and smok…

This study tests an online, therapist-guided program to help cancer survivors who have anxiety, depression, or fear of cancer returning. About 400 adults in Sweden who finished cancer treatment at least 6 months ago will take part. The goal is to see which parts of the 10-week on…

This trial tests whether duloxetine, a drug commonly used for depression, can reduce the painful nerve damage that some cancer patients experience after receiving taxane chemotherapy. The study enrolls adults with solid tumors who have at least moderate pain from this side effect…

This trial tests whether low-intensity endurance exercise can reduce cancer-related fatigue and improve quality of life in lung cancer patients. Participants will either do continuous exercise or interval exercise for 30 minutes a day, five days a week, for 12 weeks. Researchers …

This study tests whether a 20-minute exercise session on a stationary bike, done right before each radiotherapy treatment, is practical and safe for people with stage I-III non-small cell lung cancer. About 30 participants will try the program, and researchers will track how many…

This study adapts a counseling program called Meaning Centered Psychotherapy for Latinos with advanced cancer. The goal is to improve spiritual well-being and quality of life. Researchers will enroll 190 Latino adults with stage III or IV solid tumors to test the program's feasib…

This study looks at whether a computer-assisted vacuum procedure to remove blood clots from the lungs is safe and improves quality of life for cancer patients with a moderate-risk pulmonary embolism. About 25 adults with cancer and a confirmed clot in a major lung artery will tak…

This study tests an experimental drug called LY3537021 to see if it can better control nausea and vomiting caused by chemotherapy in adults with cancer. About 204 participants will receive either the drug or a placebo, and researchers will track who has no vomiting and does not n…

This study tests whether a smartphone app that tracks symptoms and gives feedback can help lung cancer patients do their prescribed rehab exercises after minimally invasive surgery. About 736 patients will use the app and be randomly assigned to get symptom alerts with clinician …

This study tests whether a short psychotherapy called brief behavioral activation (BBA) can reduce depression and anxiety and improve well-being in older adults who have survived cancer. BBA encourages people to set goals and engage in enjoyable or rewarding activities to change …

This pilot study will give 20 early-stage cancer patients a preloaded cash card with $1,000 each month. The goal is to see if this simple cash support can prevent financial hardship, like debt or missed rent, and improve treatment outcomes. Researchers will measure how many peopl…

This study tests if a steroid mouthwash can prevent or reduce mouth sores caused by the cancer drug datopotamab deruxtecan (Dato-DXd). About 100 adults with advanced breast or lung cancer will use the mouthwash and be monitored for 12 weeks. The goal is to see if this simple step…

This study tests whether a single early meeting with a psycho-oncology counselor can reduce anxiety and depression and improve quality of life in people recently diagnosed with cancer. About 148 patients will be randomly assigned to either receive this counseling plus standard ca…

This trial tests a supportive web-based app for people with advanced pancreatic, biliary tract, or non-small cell lung cancer who are about to start their first line of chemotherapy. Each week, participants answer questions about their symptoms using the app. If their answers sug…

This study is testing a new way to manage care for 33 cancer patients who take oral chemotherapy at home. Instead of going to the hospital every month just to pick up medicine, a nurse will visit them at home twice in six months. An advanced practice nurse will coordinate everyth…

This study compares a new radiation technique called lattice radiation therapy (LRT) to standard stereotactic body radiation therapy (SBRT) for people with solid tumors that have spread to soft tissues. The goal is to see if LRT shrinks tumors better and helps the immune system f…

This study tests whether personalized patient navigation can help more American Indian and Alaska Native people in Washington state get screened for lung cancer. About 237 adults aged 50-77 who smoke or recently quit will be enrolled. The goal is to see if tailored support helps …

This large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …

This study follows over 1,500 children and adults who previously received gene-modified T cell therapy for cancer. Researchers will track side effects, how long the modified cells last, and overall survival for up to 15 years. No new treatment is given—the goal is to understand l…

This study looks at how a cancer drug called pelabresib changes the way the body processes three other medicines: repaglinide (for diabetes), midazolam (a sedative), and a birth control pill. It involves 24 adults with advanced cancers who have no standard treatment options. The …

This study interviews cancer care providers, patients, and caregivers to learn their thoughts and feelings about receiving hospital-level care at home. The goal is to understand what people know and believe about home hospital care, so that future programs can be designed to bett…

This early-phase study is testing the cancer drug pelabresib in 24 people with advanced cancers who also have liver problems. The goal is to see how the liver affects the drug levels in the body. Participants will take the drug daily for 14 days, then have a week off. This resear…

Researchers are investigating whether metabolic markers measured by PET/CT scans and tumor tissue tests can predict how well early-stage non-small cell lung cancer responds to immunotherapy given before surgery. Thirty patients with stage IB to IIIA NSCLC that lacks EGFR and ALK …

This study tests a decision-making support program based on restorative justice principles, designed specifically for Black adults who are at high risk for lung cancer. The goal is to see if this approach increases understanding, trust, and willingness to get screened. Forty-five…

This study is a registry that will follow 600 people with early-stage lung cancer who undergo a surgery called segmentectomy. Participants will fill out questionnaires about their health before surgery, shortly after, and six months later. The goal is to measure how long people l…

Researchers are studying whether a next-generation radiation delivery system can run a complete treatment workflow while patients hold their breath. The trial enrolls about 20 adults with tumors in the chest or upper abdomen who are already scheduled for stereotactic body radiati…

This study collects blood, tissue, and medical information from 240 cancer patients who have had serious side effects from immunotherapy. The goal is to store these samples in a national biorepository for future research. By studying these samples, scientists hope to better predi…

This observational study follows 50 adults with locally advanced or metastatic lung cancer who are starting chemotherapy or immunotherapy. Researchers want to see how cancer-related fatigue and daily physical activity change during treatment, and whether those changes are connect…

Researchers are studying whether a blood test that looks for tiny traces of cancer DNA can identify early-stage lung cancer patients who are unlikely to need extra treatment after surgery. The trial enrolls adults with stage IB to IIIA non-small cell lung cancer who have had comp…

This study looks at how chemoradiation for locally advanced lung cancer affects the heart. Researchers will track 100 patients using heart tests, blood samples, and questionnaires. The goal is to see if tailoring treatment based on individual risk can reduce heart problems.

This study collects tissue and fluid samples from up to 5,000 cancer patients to help researchers learn more about cancer and develop new tests and treatments. Samples are taken from routine procedures or from extra biopsies done just for research. The goal is to build a resource…

This study follows people with a rare genetic condition called DICER1 syndrome, which raises the risk of certain childhood cancers like pleuropulmonary blastoma. Researchers will collect medical histories, genetic samples, and tissue from up to 1,500 participants and their relati…

This study tests whether a video and personal guidance can help Black, Latinx, and older adults with cancer get genetic testing. Genetic testing is often needed to join precision cancer trials. The goal is to make trial enrollment more equitable. About 210 people with gastrointes…

This study is building an AI tool called ACTIVATE that scans electronic health records to find cancer patients who may be eligible for clinical trials. Researchers will test whether sending alerts to doctors increases the number of patients starting trials. The goal is to make it…

This study follows about 700 cancer patients who have already received radiation therapy to understand the long-term side effects and how their disease progresses over time. No new treatments are given—researchers simply collect data from routine follow-up visits. The goal is to …

This study collects tissue samples and health information from 2000 adults with certain lung and thymic cancers. Researchers aim to better understand these diseases, which could lead to new diagnostic tools and treatments. Participants provide blood, tumor samples, and imaging da…

This study is a disease registry that will follow about 700 people with advanced non-small cell lung cancer that has a specific genetic change called METex14 skipping. Researchers will collect information on patient characteristics, treatments, and outcomes over time to better un…

This study looks at whether getting immunotherapy infusions in the morning versus the afternoon changes outcomes for people with advanced lung cancer or head and neck cancer. About 238 participants will be randomly assigned to morning or afternoon infusions. Researchers will trac…

This study tracks 125 cancer patients receiving standard chemotherapy and radiation to understand why they feel tired. Researchers will collect blood, stool, and survey data before, during, and after treatment. The goal is to find patterns that could help predict and manage fatig…

This study is testing an educational program designed to help racial and ethnic minority cancer patients make informed decisions about joining clinical trials. The program involves watching short videos and talking with a patient navigator. Researchers will measure changes in pat…

This study tests a communication tool called TrialTalk™ in cancer clinics. The goal is to see if it helps doctors and patients talk more clearly about treatment options. About 30 patients and their doctors will fill out questionnaires before and after a regular visit. The study f…

This study tests whether a newer, MRI-guided radiation method (MRgART) is gentler on the heart than standard radiation (LINAC) for people with lung, esophageal, or other chest cancers. About 60 adults will receive radiation and have their heart function checked via MRI and blood …

This study reviews medical records from 600 lung cancer patients who had surgery between 2004 and 2019. The goal is to see if the use of robotic surgery has led to more atypical segmentectomies (removing part of a lung lobe). Researchers want to understand how robotic methods com…

This study compares two types of minimally invasive lung cancer surgery: robotic-assisted (RATS) and video-assisted (VATS). It will follow 512 patients across Europe to see which technique leads to better quality of life and recovery. The goal is to help surgeons and patients mak…

This study tests whether a telementoring program called ECHO can improve the quality of palliative care for advanced cancer patients in underserved areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia. Researchers will train local doctors through online clinics and w…

This study tests a program called SUPPORT that helps Black and Latino cancer patients learn about and join clinical trials. The program includes a website and a navigator who guides patients. Researchers will see if this increases the number of patients referred to and enrolled i…

This study is testing whether smartwatches and blood tests can measure how well children recover after surgery to remove a solid tumor. About 40 children and their caregivers will wear smartwatches and answer questionnaires before surgery and for up to a year after. Researchers w…

Some cancer drugs cause rare but serious heart and metabolic problems. This study follows 5,000 cancer patients across several French hospitals who receive a dedicated heart checkup and ongoing follow-up through cardio-oncology programs. Researchers track how many patients benefi…

This study looks at medical records of 3000 people in China with early-stage non-small cell lung cancer (stages I to III). The goal is to understand what treatments patients receive, how often biomarker testing is done, and what happens to them over time. No new treatments are gi…

This study uses online surveys to explore whether cancer patients and their family members across the European Union have equal access to mental health screening and psychological support. Researchers will analyze responses from 2,000 participants to identify disparities, barrier…

Cell therapies such as CAR-T and TIL therapy are emerging options for advanced solid tumors, but their benefits are uncertain and side effects can be severe. Researchers at Zhejiang University are surveying about 420 cancer doctors and 600 patients in China to learn how each grou…

This study looks at how platinum-based chemotherapy can cause permanent hearing loss in cancer patients, and whether people from poorer backgrounds are more affected. Researchers will test hearing and thinking skills in 172 patients from North West England before and after treatm…

This study looks at whether a structured program can help more high-risk smokers get a first lung cancer screening with a CT scan. About 500 people aged 50 to 74 who smoke or recently quit will join. The goal is to see if a dedicated network makes screening easier and more effect…

This study involves 3,400 people with advanced non-small cell lung cancer to see if a new test for a protein called TROP2 works consistently across different laboratories. The goal is to ensure that doctors can reliably use this test to guide treatment decisions. Participants pro…

This study aims to collect tumor, normal tissue, and blood samples from up to 1559 people with cancers of the lung, esophagus, or pleura. Researchers will analyze genetic and epigenetic changes to better understand these diseases and identify potential markers for future treatmen…

This study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …

This study enrolls adults with cancer or benign tumors who are already participating in other trials at the National Cancer Institute. Researchers will collect and link medical records and research samples from all of a patient's past, current, and future studies. The goal is to …

This study tests a new way to increase lung cancer screening in people at high risk. Researchers will use the emergency department to identify eligible patients and offer them extra help to get a low-dose CT scan. The goal is to see if this approach works better than standard car…

This study is looking at whether regularly checking the amount of pembrolizumab in the blood of people with non-small cell lung cancer can help doctors tailor treatment. The goal is to see if this monitoring can improve how well the drug works and reduce side effects. The trial w…

This study looks at whether men and women experience different side effects from cancer immunotherapy. Researchers will track symptoms and quality of life in 100 adults starting standard immunotherapy. The goal is to better understand how sex and gender influence treatment experi…

This observational study in Vietnam looks at archived tumor samples from patients with several solid cancers, including liver, colorectal, gastric, breast, lung, endometrial, melanoma, and pancreatic cancer. Researchers will measure the presence of two proteins, ENPP1/cGAS and FA…

This study looks at how well robotic biopsies can collect enough tissue to find genetic changes linked to lung cancer. About 40 adults at high risk for lung cancer or with suspected spread to the lungs will take part. The goal is to create a databank of genetic and medical inform…

This study looks back at medical records of 200 adults in Latin America with a rare and aggressive cancer called neuroendocrine carcinoma. Researchers want to understand how patients are diagnosed, what treatments they receive, and how their disease progresses over time. The goal…

This study screens adults with certain cancers (like melanoma, lung, or colorectal cancer) to see if they qualify for experimental treatments being tested by the NCI Surgery Branch. These treatments involve taking a patient's own immune cells, growing them in a lab, and giving th…

This study follows 700 cancer patients who take blood thinners and are scheduled for surgery or medical procedures. Researchers will track how often major bleeding or clotting events occur within 30 days after the procedure. The goal is to see if current blood thinner management …

This study looks at 500 people with a rare type of lung cancer that has air-filled pockets (cysts). Researchers want to find the best way to measure these tumors to improve staging and predict outcomes. By reviewing past CT scans and health records, they hope to help doctors make…

This observational study collects tumor tissue and blood cells from 200 people with advanced solid tumors like colorectal, lung, and pancreatic cancers. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for potential fu…

This pilot study investigates whether certain molecules in the blood, called miRNAs and proteins, change during cancer treatment and whether these changes can signal early signs of heart or lung damage. Researchers will compare blood samples from patients receiving radiation or c…

This study will review health records of 60,000 adults with lung cancer in Alberta and Ontario to understand current treatments, survival rates, and healthcare costs. It aims to describe real-world patterns rather than test a new treatment. No direct benefit to participants, but …

This study looks at whether offering money for things like travel, lodging, and childcare helps more people from different backgrounds join cancer clinical trials. Researchers will track enrollment and retention of 1,200 patients who are already in a cancer trial. They will compa…

This study follows 75 people with locally advanced non-small cell lung cancer who receive a year of adjuvant immunotherapy after chemoradiotherapy. Researchers will use questionnaires to track changes in quality of life and self-reported health from the start of immunotherapy to …

This study uses surveys to understand what factors influence Chinese patients and doctors when selecting first-line EGFR-TKI therapy for advanced non-small cell lung cancer. Researchers will ask about preferences for treatment benefits, side effects, and other attributes. The goa…

This study aims to learn how genes and the environment contribute to rare tumors and cancer risk in individuals and families. Researchers will collect medical histories, genetic samples, and health data from up to 500 participants of all ages. No treatment is given; the goal is t…

This study tests whether a digital chatbot can help more adolescents and young adults (AYA) with cancer get genetic counseling and testing compared to standard remote services. About 535 participants aged 18-39 will use either a chatbot or standard telehealth. The goal is to see …

This study tests whether a new type of adaptive radiotherapy can reduce radiation exposure to the ovaries in young women (ages 18-50) receiving pelvic radiation for cancers like uterine, rectal, or cervical cancer. Using advanced imaging and an AI treatment planning system, resea…